2010 Cannabinoids Clinical Trials Terpenes 
The Cannigma
MAY 13, 2022
There have been a number of preclinical and clinical trials studying cannabis’ effects on pain. The best type of cannabis for dealing with chronic pain tends to be type I or type II strain with a terpene profile that includes linalool, pinene, beta-caryophyllene, limonene, or myrcene. Can topical terpenes alone help with pain?
Greencamp
AUGUST 16, 2018
Exploring the available research on ALS and cannabinoids. The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. The first study I will reference is from 2006, conducted on mice.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaMD
AUGUST 8, 2020
In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. However, many of these products contain a number of other cannabinoids as well. To understand cannabinoids, we need to take a closer look at the endocannabinoid system.
Green Relief
MAY 13, 2018
government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.
Green Relief
MAY 12, 2018
government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.
Cannabis Law Report
NOVEMBER 24, 2021
The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). However, from 2010, a dramatic increase is observable in articles about medicinal cannabis in the publications under analysis. years (Atakan 2012 ). Discussion.
Cannabis Law Report
JULY 12, 2019
International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.
Expert insights. Personalized for you.
111 
Let's personalize your content